Gastroesophageal cancer Header
opdivo-dtc-util-nav

Indications

Prescribing Information

Next Page Icon

Medication Guide

Next Page Icon
Potential OPDIVO® (nivolumab) user cleaning a surfboard with his friends.
Potential OPDIVO® (nivolumab) user cleaning a surfboard with his friends.

Clinical trial results for
esophageal or gastroesophageal junction
cancer after surgery

Esophageal or gastroesophageal junction
(GEJ) cancer that has been treated with
chemoradiation followed by surgery to help
prevent it from coming back

Actor portrayals.
OPDIVO is not approved for people younger
than 18 years of age.

An FDA-approved immunotherapy that helped people live longer without their cancer returning compared to placebo

About the clinical trial

In a clinical trial of 794 people who had received chemoradiation followed by surgery to remove their esophageal or GEJ cancer, 532 people were given OPDIVO and 262 people were given placebo.

People given OPDIVO lived longer without their cancer returning compared to placebo

At 22 months, half the people given OPDIVO®  remained free of their cancer returning.
OPDIVO

Half the people remained free of their cancer returning

At 11 months, half the people given a placebo remained free of their cancer returning.
Placebo

Half the people remained free of their cancer returning

People given OPDIVO after chemoradiation and surgery had a 31% lower risk of their esophageal or GEJ cancer returning compared to people given placebo.

OPDIVO will not work for everyone. Individual results may vary.

Hands exploring how OPDIVO® (nivolumab) works and learning how this treatment may help fight cancer.

How treatment works

See how this treatment may help your body fight cancer

OPDIVO® (nivolumab) side effects.

Side effects

View side effects of treatment and learn how to manage them

Nurse monitoring a gentleman's infusion of OPDIVO® (nivolumab) immunotherapy treatment.

Getting an infusion

See your recommended treatment plan and what to expect from an infusion

For adults with esophageal or gastroesophageal junction (GEJ) cancer who have been treated with chemoradiation followed by surgery to help prevent it from coming back

OPDIVO® (nivolumab) is a prescription medicine that may be used in adults to help prevent cancer of the tube that connects your throat to your stomach (esophageal cancer) or cancer where the esophagus joins the stomach (gastroesophageal junction cancer) from coming back after it has been treated with chemoradiation followed by surgery to remove the cancer, but some cancer cells were still present in the removed tumor or lymph nodes.

It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.

It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.